Publications by authors named "James Rusthoven"

Claim this Profile
P
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma.
Nicholas J Vogelzang, James J Rusthoven, James Symanowski, Claude Denham, E Kaukel

J Clin Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy.
Jane E Latz, Mats O Karlsson, James J Rusthoven, Atalanta Ghosh, Robert D Johnson

Cancer Chemother Pharmacol· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy.
Jane E Latz, James J Rusthoven, Mats O Karlsson, Atalanta Ghosh, Robert D Johnson

Cancer Chemother Pharmacol· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso.
Patricia J Hollen, Richard J Gralla, Astra M Liepa, James T Symanowski, James J Rusthoven

Support Care Cancer· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Malignant pleural mesothelioma: update, current management, and newer therapeutic strategies.
Massimo Pistolesi, James Rusthoven

Chest· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: using the LCSS-Meso conceptual model for validation.
Patricia J Hollen, Richard J Gralla, Astra M Liepa, James T Symanowski, James J Rusthoven

Cancer· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
Nicholas J Vogelzang, James J Rusthoven, James Symanowski, Claude Denham, E Kaukel

J Clin Oncol· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
Giorgio V Scagliotti, Dong-M Shin, Hedy L Kindler, Michael J Vasconcelles, Uwe Keppler, James J Rusthoven

J Clin Oncol· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pemetrexed safety and dosing strategy.
Clet Niyikiza, Axel-R Hanauske, James J Rusthoven, A Hilary Calvert, Robert Allen

Semin Oncol· December 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of marimastat (BB-2516) in malignant melanoma: a clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group.
Ian Quirt, Audley Bodurth, Reinhard Lohmann, James Rusthoven, Karl Belanger

Invest New Drugs· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.
Clet Niyikiza, Sharyn D Baker, David E Seitz, Jackie M Walling, Katrina Nelson, James J Rusthoven

Mol Cancer Ther· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis